Clorox (NYSE:CLX – Get Free Report) had its target price cut by research analysts at Citigroup from $100.00 to $97.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price objective points to a potential upside of 11.27% from the stock’s previous close.
A number of other equities research analysts also recently weighed in on CLX. Evercore set a $99.00 target price on Clorox in a research report on Tuesday, August 4th. Wells Fargo & Company decreased their price target on Clorox from $102.00 to $90.00 and set an “equal weight” rating on the stock in a report on Friday. JPMorgan Chase & Co. lifted their price objective on Clorox from $92.00 to $95.00 and gave the stock an “underweight” rating in a research report on Tuesday, August 4th. BNP Paribas Exane dropped their price objective on Clorox from $97.00 to $95.00 and set a “neutral” rating for the company in a report on Monday, July 20th. Finally, UBS Group restated a “neutral” rating on shares of Clorox in a research report on Friday. Twelve investment analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $101.40.
Get Our Latest Analysis on CLX
Clorox Price Performance
Clorox (NYSE:CLX – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.02. The firm had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.91 billion. Clorox had a net margin of 8.74% and a return on equity of 522.23%. Clorox’s revenue was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.87 EPS. Clorox has set its FY 2027 guidance at 5.700-6.000 EPS. As a group, equities analysts expect that Clorox will post 5.8 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Clorox
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Haverford Trust Co lifted its stake in Clorox by 2.8% during the fourth quarter. Haverford Trust Co now owns 3,070 shares of the company’s stock worth $310,000 after purchasing an additional 84 shares in the last quarter. Golden State Wealth Management LLC grew its position in Clorox by 28.2% in the 4th quarter. Golden State Wealth Management LLC now owns 454 shares of the company’s stock valued at $46,000 after acquiring an additional 100 shares in the last quarter. Kestra Private Wealth Services LLC increased its stake in Clorox by 1.8% during the first quarter. Kestra Private Wealth Services LLC now owns 5,957 shares of the company’s stock worth $617,000 after purchasing an additional 104 shares during the period. Johnson Financial Group Inc. lifted its position in shares of Clorox by 3.1% during the third quarter. Johnson Financial Group Inc. now owns 3,659 shares of the company’s stock worth $451,000 after purchasing an additional 109 shares in the last quarter. Finally, State of Wyoming grew its holdings in shares of Clorox by 4.7% in the second quarter. State of Wyoming now owns 2,540 shares of the company’s stock valued at $305,000 after purchasing an additional 113 shares in the last quarter. Institutional investors own 78.53% of the company’s stock.
About Clorox
The Clorox Company (NYSE: CLX) is a consumer products company that develops, manufactures and markets household, health and wellness, and lifestyle products. Its portfolio includes cleaning and disinfecting products, laundry and home-care items, food products, personal-care products, water-filtration systems, charcoal, and cat litter.
Clorox’s brands include Clorox bleach and disinfecting products, Pine-Sol, Fresh Step and Scoop Away, Kingsford, Brita, Burt’s Bees, Hidden Valley, and products marketed under the Glad name.
Read More
- Five stocks we like better than Clorox
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
- Oracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in Earnings
- TSMC Revenue Jumps 53% in August, Signaling Strong AI Chip Demand
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.
